Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharma
Woman and Man Max 99 years
Novartis Pharma GmbH
Update Il y a 4 ans
Study to assess lung function and patient preference after a 4 week treatment each with QVA149 vs. tiotropium in patients with stable chronic obstructive pulmonary disease (COPD) and moderate to severe airflow limitation who are on a tiotropium therapy
To demonstrate superiority of QVA149 (100/50 µg o.d.) as compared to tiotropium (18 µg o.d.) in terms of FEV1 1 h post-inhalation after 4 weeks of treatment in patients with stable COPD and moderate t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation
• To facilitate the management of patients on maintenance immunosuppression therapy who are completing everolimus trials, • To provide everolimus maintenance therapy through this access program and ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A study of Ofatumumab versus Rituximab in Hodgkin Lymphoma
To compare progression-free survival following therapy with single agent ofatumumab versus single agent rituximab in subjects with iNHL that has relapsed after prior rituximab-containing therapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
Study of the effect of serelaxin on high-sensitivity cardiac troponin I (hs cTnI) release in patients with chronic heart failure
To evaluate the effect of short-term i.v. administration of serelaxin in CHF patients on the geometric mean of hs-cTnI concentrations compared to placebo (both in addition to SoC) after an exercise te...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
CBHQ880A2204 : Essai de phase 2 évaluant l’efficacité du BHQ880, un anticorps neutralisant DKK1 (anti-Dickkopf1) humanisé, chez des patients ayant un myélome multiple indolent à haut risque d’évolution. [essai clos aux inclusions]
L’objectif de cet essai est de déterminer si le BHQ880 a une activité anti-myélomateuse, chez les patients ayant un myélome multiple indolent à haut risque d’évolution. Les patients recevront une per...
Country
France
organs
Myélomes
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
An interventional study of oral HDM201 in combination with oral LEE011 in adult patients with liposarcoma
Phase Ib: To determine the MTD and/or RP2D of HDM201 in combination with LEE011 in patients with liposarcoma using two different HDM201 dosing schedules. Phase2: To assess the preliminary anti-tum...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Novartis Pharma
Update Il y a 4 ans
Étude GEP-NEC : étude de phase 2 visant à évaluer l’efficacité et la sécurité d’emploi du PDR001 chez des patients ayant des tumeurs neuroendocrines non-fonctionnelles avancées ou métastatiques bien différentiées du pancréas, du tractus gastrointestinal ou du thorax ou un carcinome neuroendocrine gastroenteropancréatique peu différentié qui a progressé sous un traitement antérieur. [essai clos aux inclusions]
Les tumeurs neuroendocrines prennent naissance dans les cellules du système neuroendocrinien qui sont dispersées dans tout le corps. Ces cellules reçoivent des signaux du système nerveux et fabriquent...
Country
France
organs
Système endocrinien - autres
,
Pancréas
,
Estomac
,
Intestin
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A multi-center, randomized, double-blind, double-dummy, parallel-group dose-finding study to evaluate the change in HbA1c after 12 weeks monotherapy with seven doses of LIK066 compared with placebo or sitagliptin in patients with type 2 diabetes
To evaluate the dose-response relationship for LIK066 in terms of changes from baseline in HbA1c after 12 weeks of treatment across 7 oral doses (2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, or 150 mg q...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A twelve-week, randomized, double-blind, multi-center, placebo controlled, parallel group study to evaluate the safety and efficacy of aliskiren 150 mg when added to standard therapy in patients with stable heart failure
• Evaluate the overall safety and tolerability of aliskiren 150 mg when given in addition to standard therapy in hypertensive patients with stable heart failure.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharma Services AG
Update Il y a 4 ans
A multicenter, open-label, single-arm study to evaluate the single-dose pharmacokinetics, acceptability and safety of famciclovir oral pediatric formulation in infants 1 month to <1 year of age with herpes simplex or varicella zoster virus infections
To evaluate the pharmacokinetics of a single dose of famciclovir in infants 1 month to <1 year of age who are at risk of, or who have herpes simplex virus infections.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
15
16
17
18
19
20
21
22
23
24
Next